We Give Shareholders a Voice
that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Celgene Corporation (NASDAQGS: CELG) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the transaction, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene stock they own. Celgene shareholders will also receive a Contingent Value Right (CVR) equal to $9.00.
The Celgene merger investigation concerns whether the Board of Celgene breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Bristol-Myers Squibb Company is underpaying for Celgene shares, thus unlawfully harming Celgene shareholders.
To receive more information, please fill out the form.